LivaNova Receives a Buy from Berenberg Bank

By Jason Carr

In a report issued on August 9, Scott Bardo from Berenberg Bank assigned a Buy rating to LivaNova (NASDAQ: LIVN), with a price target of $70. The company’s shares closed yesterday at $61.78, close to its 52-week high of $64.95.

Bardo has an average return of 16.5% when recommending LivaNova.

According to TipRanks.com, Bardo is ranked #1318 out of 4628 analysts.

LivaNova has an analyst consensus of Moderate Buy, with a price target consensus of $67.50.

LivaNova’s market cap is currently $2.97B and has a P/E ratio of 108.39. The company has a book value ratio of 1.7137.

Based on the recent corporate insider activity of 27 insiders, corporate insider sentiment is neutral on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

LivaNova Plc is a global medical technology company specializing in the areas of Cardiac Surgery, Neuromodulation and Cardiac Rhthym Management. The company was founded on October 19, 2015 and is headquartered in London, the United Kingdom.